($GANX): March Update- Evidence of Disease Modification Keeps Getting Stronger
Gain Therapeutics has demonstrated statistically significant UPDRS functional improvement and correlated biomarker evidence (GluSph reduction and DDC normalization) showing disease modification in Parkinson's disease. The company will present additional evidence at the AD/PD conference on 3/17, and with strong institutional ownership growth and elevated short interest, an acquisition or partnership appears likely.
At post $2.71·Now $1.13-58.3% since postedas of Oct 30, 4:45 PM ET
1d-3.0%
3d-7.4%
1w+8.1%
1m-28.4%
3m-28.0%
6m-34.7%
1y—
$GANX- CEO interview just came out-- dispels any misconceptions
GANX's CEO interview reveals the company has achieved disease-modifying evidence for Parkinson's through their GluSph biomarker, which was a pre-specified FDA endpoint showing reduction in glutathione depletion and improvement in UPDRS scores. The author believes the recent sell-off was an overreaction and that GANX's drug will be the first disease-modifying treatment for Parkinson's, making it an attractive entry point at a discount.
At post $2.88·Now $1.13-60.7% since postedas of Oct 30, 4:45 PM ET
1d—
3d+11.0%
1w+9.6%
1m-37.0%
3m-33.9%
6m-38.1%
1y—
"Lightning in a Bottle": "Groundbreaking Early Readout For Gain Therapeutics Gives It A Shot At First Disease-Modifying Drug For Parkinson’s" $GANX
Gain Therapeutics' GT-02287 represents a potential multi-billion-dollar breakthrough for Parkinson's disease, addressing up to 90% of the patient population through a novel mechanism. With analyst price targets of $18-$34 per share, strong preclinical/early clinical data, and likely acquisition interest from major pharma (following recent large biotech partnerships), the stock is significantly undervalued at current single-digit levels ahead of imminent data release.
At post $3.95·Now $1.13-71.4% since postedas of Oct 30, 4:45 PM ET
1d-2.3%
3d-43.0%
1w-19.2%
1m-44.3%
3m-38.5%
6m-57.5%
1y—
$GANX — The Most Asymmetric Setup I’ve Ever Seen (And the Clock Is Ticking)
Gain Therapeutics' GT-02287 shows consistent, positive clinical progress with strong phase 1b biomarker improvements and patient/clinician enthusiasm suggesting potential for the first truly disease-modifying Parkinson's drug. CEO's confident public statements, upcoming data readout within days, and asymmetric risk/reward (especially for GBA1 subgroup) suggest significant overnight upside similar to recent biotech catalysts, with minimal downside.
At post $4.11·Now $1.13-72.5% since postedas of Oct 30, 4:45 PM ET
1d+0.7%
3d+0.7%
1w-45.3%
1m-43.8%
3m-30.9%
6m-59.9%
1y—
Inflammation: The Common Denominator in Parkinson's Disease ($GANX)
GT-02287, an allosteric GCase modulator developed by Gain Therapeutics, targets the self-amplifying inflammation-mitochondria-lysosome doom loop in Parkinson's disease by restoring mitochondrial energy and lysosomal clearance. Phase 1 data shows target engagement, CNS exposure, mitochondrial/lysosomal rescue, and directional improvements in UPDRS over 90 days, positioning it as a potential disease-modifying therapy rather than merely symptomatic relief.
At post $3.99·Now $1.13-71.7% since postedas of Oct 30, 4:45 PM ET
1d—
3d+4.8%
1w+3.8%
1m-36.1%
3m-23.6%
6m-57.4%
1y—
Parkinson's Drug On Verge Of Historical Data Release (likely acquired at 10X or more in coming month)s: GANX
Gain Therapeutics' Parkinson's drug GT-02287 appears poised for a major biomarker data release in 4–5 weeks that could confirm disease modification and trigger acquisition interest. With a sub-$100M market cap, even a modest $1B+ acquisition would deliver 10x+ returns, making this a high-asymmetry setup.
At post $2.95·Now $1.13-61.7% since postedas of Oct 30, 4:45 PM ET
1d+1.4%
3d-4.1%
1w-6.8%
1m+40.3%
3m-39.7%
6m-38.3%
1y—